Adaptive Biotechnologies Files DEF 14A with Executive Compensation Details
Ticker: ADPT · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1478320
| Field | Detail |
|---|---|
| Company | Adaptive Biotechnologies Corp (ADPT) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, equity-awards, corporate-governance
TL;DR
Adaptive Bio files DEF 14A detailing exec comp & equity awards for 2020-2024.
AI Summary
Adaptive Biotechnologies Corp filed a DEF 14A on April 29, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate governance matters. Key information includes data on equity awards granted and outstanding for the fiscal years 2020 through 2024, with specific figures for "PeoMember" and "NonPeoNeoMember" categories.
Why It Matters
This filing provides transparency into how Adaptive Biotechnologies compensates its top executives, which can influence investor decisions and employee morale.
Risk Assessment
Risk Level: low — This is a routine filing providing information on executive compensation and corporate governance, not indicating immediate financial distress or significant operational changes.
Key Numbers
- 2020-2024 — Fiscal Years Reported (Covers a range of years for executive equity award data.)
Key Players & Entities
- Adaptive Biotechnologies Corp (company) — Filer of the DEF 14A
- 20250429 (date) — Filing date of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for which data is reported
- 2020-01-01 (date) — Start of reporting period for equity awards
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used to solicit proxies from shareholders when the company is asking them to vote on important matters at a shareholder meeting, and it also provides detailed information on executive compensation and corporate governance.
What specific types of compensation data are detailed in this filing?
This filing details executive compensation, specifically focusing on equity awards granted and outstanding, including their fair value at year-end and vesting dates for the fiscal years 2020 through 2024.
Who are the 'PeoMember' and 'NonPeoNeoMember' categories referring to?
These categories likely refer to different groups of individuals within the company for compensation reporting purposes, such as 'Principal Executive Officer' (PEO) and other 'Neolisted' or 'Non-PEO' executive officers.
What is the significance of the 'ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember' data point?
This data point represents the year-end fair value of equity awards that were granted in the covered year, are still outstanding, and have not yet vested, for specific member categories.
When is the next shareholder meeting or vote expected based on this filing's period of report?
The filing's 'Conformed Period of Report' is 20250610, suggesting matters related to a shareholder meeting around that date are being addressed.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Adaptive Biotechnologies Corp (ADPT).